Skip to main content
. 2023 Aug 11;15(8):2124. doi: 10.3390/pharmaceutics15082124

Figure 5.

Figure 5

Two-dimensional structures of (A) 5-ALA; (B) verteporfin; (C) 5,10,15,20-(Tetra-N-methyl-4-pyridyl)porphyrin tetratosylate; (D) PpIX; (E) palladium-meso-tetra (4-carboxyphenyl) porphyrin; (F) (5,10,15,20-(Tetra-4-sulfonate phenyl) porphyrin tetraammonium.